Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) Return on Equity (2020 - 2025)

Historic Return on Equity for C4 Therapeutics (CCCC) over the last 6 years, with Q3 2025 value amounting to 0.73%.

  • C4 Therapeutics' Return on Equity fell 2900.0% to 0.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.73%, marking a year-over-year decrease of 2900.0%. This contributed to the annual value of 0.46% for FY2024, which is 400.0% up from last year.
  • Latest data reveals that C4 Therapeutics reported Return on Equity of 0.73% as of Q3 2025, which was down 2900.0% from 0.6% recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Return on Equity ranged from a high of 0.21% in Q4 2021 and a low of 0.73% during Q3 2025
  • Over the past 5 years, C4 Therapeutics' median Return on Equity value was 0.43% (recorded in 2024), while the average stood at 0.43%.
  • The largest annual percentage gain for C4 Therapeutics' Return on Equity in the last 5 years was 8500bps (2021), contrasted with its biggest fall of -6000bps (2021).
  • Over the past 5 years, C4 Therapeutics' Return on Equity (Quarter) stood at 0.21% in 2021, then tumbled by -97bps to 0.42% in 2022, then tumbled by -36bps to 0.57% in 2023, then grew by 20bps to 0.46% in 2024, then tumbled by -58bps to 0.73% in 2025.
  • Its last three reported values are 0.73% in Q3 2025, 0.6% for Q2 2025, and 0.5% during Q1 2025.